miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients

被引：619

作者：

Lanczky, Andras ^{[1
]}

Nagy, Adam ^{[1
,2
]}

Bottai, Giulia ^{[3
]}

Munkacsy, Gyongyi ^{[1
,4
]}

Szabo, Andras ^{[2
]}

Santarpia, Libero ^{[3
]}

Gyorffy, Balazs ^{[1
,2
]}

机构：

[1] MTA TTK Lendulet Canc Biomarker Res Grp, Magyar Tudosok Korutja 2, H-1117 Budapest, Hungary

[2] Semmelweis Univ, Dept Pediat, Budapest, Hungary

[3] Humanitas Clin & Res Inst, Oncol Expt Therapeut Unit, Via Manzoni 113, I-20089 Rozzano Milan, Italy

[4] MTA SE Pediat & Nephrol Res Grp, Budapest, Hungary

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2016年 / 160卷 / 03期

基金：

匈牙利科学研究基金会;

关键词：

Breast cancer; Biomarkers; MicroRNAs; Gene expression; Prognosis; Survival; MICROARRAY DATA; ONLINE TOOL; BIOMARKERS; MICRORNAS; THERAPY; DYSREGULATION; PROGNOSIS; PATHWAYS; MARKERS;

D O I：

10.1007/s10549-016-4013-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The proper validation of prognostic biomarkers is an important clinical issue in breast cancer research. MicroRNAs (miRNAs) have emerged as a new class of promising breast cancer biomarkers. In the present work, we developed an integrated online bioinformatic tool to validate the prognostic relevance of miRNAs in breast cancer. A database was set up by searching the GEO, EGA, TCGA, and PubMed repositories to identify datasets with published miRNA expression and clinical data. Kaplan-Meier survival analysis was performed to validate the prognostic value of a set of 41 previously published survival-associated miRNAs. All together 2178 samples from four independent datasets were integrated into the system including the expression of 1052 distinct human miRNAs. In addition, the web-tool allows for the selection of patients, which can be filtered by receptors status, lymph node involvement, histological grade, and treatments. The complete analysis tool can be accessed online at: . We used this tool to analyze a large number of deregulated miRNAs associated with breast cancer features and outcome, and confirmed the prognostic value of 26 miRNAs. A significant correlation in three out of four datasets was validated only for miR-29c and miR-101. In summary, we established an integrated platform capable to mine all available miRNA data to perform a survival analysis for the identification and validation of prognostic miRNA markers in breast cancer.

引用

页码：439 / 446

页数：8

共 32 条

[1] SurvMicro: assessment of miRNA-based prognostic signatures for cancer clinical outcomes by multivariate survival analysis [J].

Aguirre-Gamboa, Raul ;

Trevino, Victor .

BIOINFORMATICS, 2014, 30 (11) :1630-1632

[2] MIRUMIR: an online tool to test microRNAs as biomarkers to predict survival in cancer using multiple clinical data sets [J].

Antonov, A. V. ;

Knight, R. A. ;

Melino, G. ;

Barlev, N. A. ;

Tsvetkov, P. O. .

CELL DEATH AND DIFFERENTIATION, 2013, 20 (02) :367-367

[3] MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer [J].

Bertoli, Gloria ;

Cava, Claudia ;

Castiglioni, Isabella .

THERANOSTICS, 2015, 5 (10) :1122-1143

[4] MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype [J].

Blenkiron, Cherie ;

Goldstein, Leonard D. ;

Thorne, Natalie P. ;

Spiteri, Inmaculada ;

Chin, Suet-Feung ;

Dunning, Mark J. ;

Barbosa-Morais, Nuno L. ;

Teschendorff, Andrew E. ;

Green, Andrew R. ;

Ellis, Ian O. ;

Tavare, Simon ;

Caldas, Carlos ;

Miska, Eric A. .

GENOME BIOLOGY, 2007, 8 (10)

[5] microRNA-Associated Progression Pathways and Potential Therapeutic Targets Identified by Integrated mRNA and microRNA Expression Profiling in Breast Cancer [J].

Buffa, Francesca M. ;

Camps, Carme ;

Winchester, Laura ;

Snell, Cameron E. ;

Gee, Harriet E. ;

Sheldon, Helen ;

Taylor, Marian ;

Harris, Adrian L. ;

Ragoussis, Jiannis .

CANCER RESEARCH, 2011, 71 (17) :5635-5645

[6] miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer [J].

Chen, Bo ;

Tang, Hailin ;

Liu, Xiaoping ;

Liu, Peng ;

Yang, Lu ;

Xie, Xinhua ;

Ye, Feng ;

Song, Cailu ;

Xie, Xiaoming ;

Wei, Weidong .

CANCER LETTERS, 2015, 356 (02) :410-417

[7] WBSMDA: Within and Between Score for MiRNA-Disease Association prediction [J].

Chen, Xing ;

Yan, Chenggang Clarence ;

Zhang, Xu ;

You, Zhu-Hong ;

Deng, Lixi ;

Liu, Ying ;

Zhang, Yongdong ;

Dai, Qionghai .

SCIENTIFIC REPORTS, 2016, 6

[8] MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients [J].

De Mattos-Arruda, Leticia ;

Bottai, Giulia ;

Nuciforo, Paolo G. ;

Di Tommaso, Luca ;

Giovannetti, Elisa ;

Peg, Vicente ;

Losurdo, Agnese ;

Perez-Garcia, Jose ;

Masci, Giovanna ;

Corsi, Fabio ;

Cortes, Javier ;

Seoane, Joan ;

Calin, George A. ;

Santarpia, Libero .

ONCOTARGET, 2015, 6 (35) :37269-37280

[9] Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control [J].

de Rinaldis, Emanuele ;

Gazinska, Patrycja ;

Mera, Anca ;

Modrusan, Zora ;

Fedorowicz, Grazyna M. ;

Burford, Brian ;

Gillett, Cheryl ;

Marra, Pierfrancesco ;

Grigoriadis, Anita ;

Dornan, David ;

Holmberg, Lars ;

Pinder, Sarah ;

Tutt, Andrew .

BMC GENOMICS, 2013, 14

[10] Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer [J].

Dowsett, Mitch ;

Dunbier, Anita K. .

CLINICAL CANCER RESEARCH, 2008, 14 (24) :8019-8026

← 1 2 3 4 →